References
- Wrensch M., Minn Y., Chew T., Bondy M., Berger M. S. Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro‐oncology 2002; 4: 278–99
- Kibirige M. S., Birch J. M., Campbell R. H., Gattamaneni H. R., Blair V. A review of astrocytoma in childhood. Pediatr Hematol Oncol 1989; 6: 319–29
- Newton H. B. Molecular neuro‐oncology and development of targeted therapeutic strategies for brain tumors. Part 2: PI3K/Akt/PTEN, mTOR, SHH/PTCH and angiogenesis. Expert Rev Anticancer Ther 2004; 4: 105–28
- Duerr E. M., Rollbrocker B., Hayashi Y., Peters N., Meyer‐Puttlitz B., Louis D. N., et al. PTEN mutations in gliomas and glioneuronal tumors. Oncogene 1998; 16: 2259–64
- James C. D., Galanis E., Frederick L., Kimmel D. W., Cunningham J. M., Atherton‐Skaff P. J., et al. Tumor suppressor gene alterations in malignant gliomas: histopathological associations and prognostic evaluation. Int J Oncol 1999; 15: 547–53
- Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S. I., et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997; 275: 1943–7
- Furnari F. B., Lin H., Huang H. S., Cavenee W. K. Growth suppression of glioma cells by PTEN requires a functional phosphatase catalytic domain. Proc Natl Acad Sci USA 1997; 94: 12479–84
- Cheney I. W., Johnson D. E., Vaillancourt M. T., Avanzini J., Morimoto A., Demers G. W., et al. Suppression of tumorigenicity of glioblastoma cells by adenovirus‐mediated MMAC1/PTEN gene transfer. Cancer Res 1998; 58: 2331–4
- Furnari F. B., Huang H. J., Cavenee W. K. The phosphoinositol phosphatase activity of PTEN mediates a serum‐sensitive G1 growth arrest in glioma cells. Cancer Res 1998; 58: 5002–8
- Tamura M., Gu J., Tran H., Yamada K. M. PTEN gene and integrin signaling in cancer. J Natl Cancer Inst 1999; 91: 1820–8
- Collins V. P. Brain tumours: classification and genes. J Neurol Neurosurg Psychiatry 2004; 75 Suppl 2: ii2–11
- Steck P. A., Pershouse M. A., Jasser S. A., Yung W. K., Lin H., Ligon A. H., et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1997; 15: 356–62
- Izumoto S., Ohnishi T., Kanemura H., Arita N., Maruno M., Moriuchi T., et al. PTEN mutations in malignant gliomas and their relation with meningeal gliomatosis. J Neurooncol 2001; 53: 21–6
- Chiariello E., Roz L., Albarosa R., Magnani I., Finocchiaro G. PTEN/MMAC1 mutations in primary glioblastomas and short‐term cultures of malignant gliomas. Oncogene 1998; 16: 541–5
- Rustia A., Wierzbicki V., Marrocco L., Tossini A., Zamponi C., Lista F. Is exon 5 of the PTEN/MMAC1 gene a prognostic marker in anaplastic glioma?. Neurosurg Rev 2001; 24: 97–102
- Koul D., Jasser S. A., Lu Y., Davies M. A., Shen R., Shi Y., et al. Motif analysis of the tumor suppressor gene MMAC/PTEN identifies tyrosines critical for tumor suppression and lipid phosphatase activity. Oncogene 2002; 21: 2357–64
- Whang Y. E., Wu X., Suzuki H., Reiter R. E., Tran C., Vessella R. L., et al. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci USA 1998; 95: 5246–50
- Sano T., Lin H., Chen X., Langford L. A., Koul D., Bondy M. L., et al. Differential expression of MMAC/PTEN in glioblastoma multiforme: relationship to localization and prognosis. Cancer Res 1999; 59: 1820–4
- Zhou Y. H., Tan F., Hess K. R., Yung W. K. The expression of PAX6, PTEN, vascular endothelial growth factor, and epidermal growth factor receptor in gliomas: relationship to tumor grade and survival. Clin Cancer Res 2003; 9: 3369–75